Incremental value of cystatin C over conventional renal metrics for predicting clinical response and outcomes in cardiac resynchronization therapy: The BIOCRT study

被引:10
作者
Chatterjee, Neal A. [1 ]
Singh, Jagmeet P. [1 ,2 ]
Szymonifka, Jackie [3 ,4 ]
Deano, Roderick C. [3 ,4 ]
Thai, Wai-ee [5 ]
Wai, Bryan [5 ]
Min, James K. [3 ,4 ]
Januzzi, James L. [1 ]
Truong, Quynh A. [3 ,4 ]
机构
[1] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA USA
[2] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiac Arrhythmia Serv, Boston, MA USA
[3] New York Presbyterian Hosp, Dalio Inst Cardiovasc Imaging, New York, NY 10021 USA
[4] Weill Cornell Med Coll, New York, NY 10021 USA
[5] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiac MR PET CT Program, Boston, MA USA
关键词
Cardiac resynchronization; Heart failure; Biomarkers; Cystatin C; GLOMERULAR-FILTRATION-RATE; CHRONIC HEART-FAILURE; KIDNEY-DISEASE; MORTALITY; CREATININE; EVENTS; CARE;
D O I
10.1016/j.ijcard.2015.12.002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Despite the benefit of CRT in select patients with heart failure (HF), there remains significant need for predicting those at risk for adverse outcomes for this effective but costly therapy. CysC, an emerging marker of renal function, is predictive of worsening symptoms and mortality in patients with HF. This study assessed the utility of baseline and serial measures of cystatin C (CysC), compared to conventional creatinine-based measures of renal function (estimated glomerular filtration rate, eGFR), in predicting clinical outcomes following cardiac resynchronization therapy (CRT). Methods: In 133 patients, we measured peripheral venous (PV) and coronary sinus (CS) CysC concentrations and peripheral creatinine levels at the time of CRT implant. Study endpoints included clinical response to CRT at 6 months and major adverse cardiac events (MACE) at 2 years. Results: While all 3 renal metrics were predictive of MACE (all adjusted p <= 0.02), only CysC was associated with CRT non-response at 6 months (adjusted odds ratio 3.6, p = 0.02). CysC improved prediction of CRT non-response (p <= 0.003) in net reclassification index analysis compared to models utilizing standard renal metrics. Serial CysC >1 mg/L was associated with 6-month CRT non-response and reduced 6-minute walk distance as well as 2-year MACE (all p <= 0.04). Conclusion: In patients undergoing CRT, CysC demonstrated incremental benefit in the prediction of CRT non-response when compared to standard metrics of renal function. Baseline and serial measures of elevated CysC were predictive of CRT non-response and functional status at 6 months as well as long-term clinical outcomes. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:43 / 49
页数:7
相关论文
共 22 条
[1]   Cystatin C and NT-proBNP, a powerful combination of biomarkers for predicting cardiovascular mortality in elderly patients with heart failure: results from a 10-year study in primary care [J].
Alehagen, Urban ;
Dahlstrom, Ulf ;
Lindahl, Tomas L. .
EUROPEAN JOURNAL OF HEART FAILURE, 2009, 11 (04) :354-360
[2]   Multidisciplinary care of patients receiving cardiac resynchronization therapy is associated with improved clinical outcomes [J].
Altman, Robert K. ;
Parks, Kimberly A. ;
Schlett, Christopher L. ;
Orencole, Mary ;
Park, Mi-Young ;
Truong, Quynh A. ;
Deeprasertkul, Peerawut ;
Moore, Stephanie A. ;
Barrett, Conor D. ;
Lewis, Gregory D. ;
Das, Saumya ;
Upadhyay, Gaurav A. ;
Heist, E. Kevin ;
Picard, Michael H. ;
Singh, Jagmeet P. .
EUROPEAN HEART JOURNAL, 2012, 33 (17) :2181-2188
[3]   Hyperphosphatemia aggravates cardiac fibrosis and microvascular disease in experimental uremia [J].
Amann, K ;
Törnig, J ;
Kugel, B ;
Gross, ML ;
Tyralla, K ;
El-Shakmak, A ;
Szabo, A ;
Ritz, E .
KIDNEY INTERNATIONAL, 2003, 63 (04) :1296-1301
[4]   Cystatin C, a novel measure of renal function, is an independent predictor of cardiac events in patients with heart failure [J].
Arimoto, T ;
Takeishi, Y ;
Niizeki, T ;
Takabatake, N ;
Okuyama, H ;
Fukui, A ;
Tachibana, H ;
Nozaki, N ;
Hirono, O ;
Tsunoda, Y ;
Miyashita, T ;
Shishido, T ;
Takahashi, H ;
Koyama, Y ;
Kubota, I .
JOURNAL OF CARDIAC FAILURE, 2005, 11 (08) :595-601
[5]   Cardiac resynchronization therapy - Part 1 - Issues before device implantation [J].
Bax, JJ ;
Abraham, T ;
Barold, SS ;
Breithardt, OA ;
Fung, JWH ;
Garrigue, S ;
Gorcsan, J ;
Hayes, DL ;
Kass, DA ;
Knuuti, J ;
Leclercq, C ;
Linde, C ;
Mark, DB ;
Monaghan, MJ ;
Nihoyannopoulos, P ;
Schalij, MJ ;
Stellbrink, C ;
Yu, CM .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 46 (12) :2153-2167
[6]   Cystatin C Identifies Patients With Stable Chronic Heart Failure at Increased Risk for Adverse Cardiovascular Events [J].
Dupont, Matthias ;
Wu, Yuping ;
Hazen, Stanley L. ;
Tang, W. H. Wilson .
CIRCULATION-HEART FAILURE, 2012, 5 (05) :602-609
[7]   Chronic kidney disease and functional limitation in older people: Health, aging and body composition study [J].
Fried, Linda F. ;
Lee, Jung Sun ;
Shlipak, Michael ;
Chertow, Glenn M. ;
Green, Christie ;
Ding, Jingzhong ;
Harris, Tamara ;
Newman, Anne B. .
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2006, 54 (05) :750-756
[8]   Cardiac Resynchronization Therapy in CKD: A Systematic Review [J].
Garg, Neha ;
Thomas, George ;
Jackson, Gregory ;
Rickard, John ;
Nally, Joseph V., Jr. ;
Tang, W. H. Wilson ;
Navaneethan, Sankar D. .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2013, 8 (08) :1293-1303
[9]   Diagnostic accuracies of plasma creatinine, cystatin C, and glomerular filtration rate calculated by the Cockcroft-Gault and Levey (MDRD) formulas [J].
Harmoinen, A ;
Lehtimäki, T ;
Korpela, M ;
Turjanmaa, V ;
Saha, H .
CLINICAL CHEMISTRY, 2003, 49 (07) :1223-1225
[10]   Renal function as a predictor of outcome in a broad spectrum of patients with heart failure [J].
Hillege, HL ;
Nitsch, D ;
Pfeffer, MA ;
Swedberg, K ;
McMurray, JJV ;
Yusuf, S ;
Granger, CB ;
Michelson, EL ;
Östergren, J ;
Cornel, JH ;
de Zeeuw, D ;
Pocock, S ;
van Veldhuisen, DJ .
CIRCULATION, 2006, 113 (05) :671-678